VKTX logo

VKTXViking Therapeutics Inc

$29.06
$0.45
(1.57%)
Today
Updated: 01:56 PM EDT
EarningsJul 29
Mkt Cap$3.32B
Vol620,411.00
News
all
press releases
Viking Therapeutics Appoints Hubert Chen As Chief Medical Officer
(RTTNews) - Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, Thursday announced that it has appointed Hubert Chen, as its Chief Medical Officer...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer PR Newswire SAN DIEGO, June 11, 2026 Experienced Biotech Leader with More than Two Decades of Experience Advancing...
PR Newswire
News Placeholder
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $27.73, marking a -5.13% move from the previous day.
Zacks
News Placeholder
Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%
Key PointsThe global market for drugs that treat obesity could be worth $150 billion by 2035...
Nasdaq News: Markets
News Placeholder
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
News Placeholder
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.
Zacks
News Placeholder
Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?
NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.
Zacks
News Placeholder
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
Zacks
News Placeholder
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?
Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.
Zacks
News Placeholder
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock
Key PointsEli Lilly and Novo Nordisk are much larger companies and already have oral weight loss pills on the market...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.